Evidence map›Paper›PMID 39328404›Full record

ArticleFrontiers in immunology2024

Peripheral NK cell phenotypic alteration and dysfunctional state post hepatitis B subviral particles stimulation in CHB patients: evading immune surveillance.

Mohamed A Selim, Reda A Suef, Ebrahim Saied, Mostafa A Abdel-Maksoud, Saeedah Musaed Almutairi, Mohammed Aufy, Adel A Mousa, Mohamed T M Mansour, Mohamed M S Farag

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. [Current status of research on the impairment of natural killer cell function caused by hepatitis B virus infection].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  5. Review
  6. Unveiling low level viremia in chronic hepatitis B: challenges and new horizons.Frontiers in cellular and infection microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamed A SelimBotany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.
Reda A SuefBotany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.
Ebrahim SaiedBotany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.
Mostafa A Abdel-MaksoudDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Saeedah Musaed AlmutairiDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Mohammed AufyDepartment of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Adel A MousaBotany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.
Mohamed T M MansourVirology and Immunology Department, National Cancer Institute, Cairo University and Childern's Cancer Hospital, Cairo, Egypt.
Mohamed M S FaragBotany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The relationship between chronic hepatitis B (CHB) infection and natural killer (NK) cell dysfunction is well-established, but the specific role of HBV viral antigens in driving NK cell impairment in patients with CHB remains unclear. This study investigates the modulatory effects of hepatitis B virus subviral particles (HBVsvp, a representative model for HBsAg) on the phenotypic regulation (activating and inhibitory receptors), cytokine production and cytotoxic potential of peripheral blood mononuclear cell-derived natural killer cells (PBMCs-derived NK cell), which contributes to NK cell dysfunction in CHB infection, potentially serving as an effective HBV immune evasion strategy by the virus. Methods: NK cells were isolated from peripheral blood of patients with CHB (n=5) and healthy individuals (n=5), stimulated with HBVsvp. Subsequent flow cytometric characterization involved assessing changes in activating (NKp46 and NKG2D) and inhibitory (CD94) receptors expression, quantifying TNF-α and IFN- γ cytokine secretion, and evaluating the cytotoxic response against HepG2.2.15 cells with subsequent HBVsvp quantification. Results: In CHB patients, Conclusion: These findings suggest that HBVsvp may induce dysfunctional NK cell responses characterized by phenotypic imbalance with subsequent reduction in cytokine and cytotoxic levels, indicating HBVsvp immunosuppressive effect that compromises antiviral defense in CHB patients. These data enhance our understanding of NK cell interactions with HBsAg and highlight the potential for targeting CD94 inhibitory receptors to restore NK cell function as an immunotherapeutic approach. Further clinical research is needed to validate these observations and establish their utility as reliable biomarkers.

Indexed as

Hepatitis B, ChronicHepatitis B virusKiller Cells, NaturalAdultCytokinesCytotoxicity, ImmunologicFemaleHepatitis B Surface AntigensHep G2 CellsHumansImmunologic SurveillanceMaleMiddle AgedNatural Cytotoxicity Triggering Receptor 1NK Cell Lectin-Like Receptor Subfamily DNK Cell Lectin-Like Receptor Subfamily KCytokinesHepatitis B Surface AntigensKLRK1 protein, humanNatural Cytotoxicity Triggering Receptor 1NK Cell Lectin-Like Receptor Subfamily DNK Cell Lectin-Like Receptor Subfamily KCD94 inhibitory receptorchronic hepatitis B (CHB)cytokineHbsAgHB subviral particles (HBVsvp)immunotherapynatural killer (NK) cellsNKp46 and NKG2D activating receptors

Identifiers

PMID39328404
PMCPMC11424423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.